Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors

#643

Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.

Aim(s): We therefore investigated the anti-tumor activity and safety profile of pazopanib, a multi-target drug with antiangiogenic activity in patients with metastatic GEP NETs.

Materials and methods: This was a non-randomized, open-labeled, single center phase II study. Pazopanib was orally administered at a dose of 800 mg daily continuously with a 28-day cycle. The primary end point was an objective response rate according to RECIST version 1.1. The secondary endpoints were progression-free survival, overall survival and safety. An independent review of objective response was planned. Correlative biomarker analyses were performed.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Park Y

Authors: Park Y, Ahn H, Lee J, Choi J, Kim K,

Keywords: Pazopanib, GEP-NETs,